Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.56 |
| ▸ | ATR | Q13535 | 9/20 | 0.49 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL488626 | 1.00 | KCNH2 (0.56) | KCNH2ATRCCNE2CCNE1CDK2 | |
| SCHEMBL488175 | 0.93 | ATR (0.51) | KCNH2ATRAURKAAURKBABL1 | |
| SCHEMBL30454557 | 0.93 | ATR (0.51) | KCNH2ATRAURKAAURKBABL1 | |
| SCHEMBL488677 | 0.87 | ATR (0.53) | KCNH2ATR | |
| SCHEMBL30453867 | 0.87 | ATR (0.53) | KCNH2ATR | |
| SCHEMBL487938 | 0.85 | ATR (0.54) | KCNH2ATR | |
| SCHEMBL30453653 | 0.85 | ATR (0.54) | KCNH2ATR | |
| SCHEMBL30454652 | 0.84 | KCNH2 (0.56) | KCNH2 | |
| SCHEMBL488288 | 0.84 | KCNH2 (0.56) | KCNH2 | |
| SCHEMBL488522 | 0.84 | MAP4K4 (0.43) | KCNH2ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113181362-B | Medicament for preventing and/or treating amyotrophic lateral sclerosis | 国立大学法人京都大学 | 2023-06-13 | — | — | CN | disclosed |